PharmaSGP Holding Soars with Impressive Revenue Growth in Q1 2024 Business Development

• PharmaSGP Holding SE reported a 25.6% increase in revenues to €30.1 million in Q1 2024, compared to €24.0 million in the same period in 2023.
• The company's adjusted EBITDA rose from €7.0 million to €8.9 million in the first three months of 2024.
• The adjusted EBITDA margin increased quarter-on-quarter to 29.4% from 29.2% in the prior-year quarter.
• The company's revenue growth reflects its potential in foreign markets, according to CFO Michael Rudolf.
• For the financial year 2024, revenues are expected to be between €107.0 million and €112.0 million, with adjusted EBITDA expected to increase to between €35.0 million and €38.0 million.
• PharmaSGP will publish its full statement for the first three months of 2024 on May 28, 2024.

The price of PharmaSGP Holding at the time of the news was 22,800EUR and did not change compared to the previous day.
21 minutes after the article was published, the price was 23,000EUR this corresponds to a plus of +0,88 % since publication.

PharmaSGP Holding

-1,71 %

+1,77 %

+1,77 %

+6,48 %

-10,51 %

-1,29 %

-28,13 %

-28,13 %

-34,29 %

ISIN:DE000A2P4LJ5WKN:A2P4LJ

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max